Pacific Biosciences of California (PACB) Earning Positive Press Coverage, Analysis Shows

News articles about Pacific Biosciences of California (NASDAQ:PACB) have trended positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a media sentiment score of 0.42 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.9877480295526 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s rankings:

Shares of Pacific Biosciences of California (NASDAQ:PACB) opened at $2.77 on Friday. The company has a current ratio of 3.75, a quick ratio of 3.15 and a debt-to-equity ratio of 0.10. Pacific Biosciences of California has a 12-month low of $2.66 and a 12-month high of $7.14.

Pacific Biosciences of California (NASDAQ:PACB) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.01. The business had revenue of $23.54 million for the quarter, compared to the consensus estimate of $28.29 million. Pacific Biosciences of California had a negative return on equity of 97.50% and a negative net margin of 95.97%. The company’s revenue for the quarter was down 6.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.19) earnings per share. analysts anticipate that Pacific Biosciences of California will post -0.88 EPS for the current year.

A number of research firms recently weighed in on PACB. Zacks Investment Research downgraded Pacific Biosciences of California from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. CL King downgraded Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $6.80 price target for the company. in a research report on Thursday, September 28th. Finally, First Analysis downgraded Pacific Biosciences of California from an “overweight” rating to an “equal weight” rating and set a $4.00 price target for the company. in a research report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Pacific Biosciences of California currently has a consensus rating of “Hold” and a consensus target price of $6.27.

COPYRIGHT VIOLATION WARNING: This report was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://weekherald.com/2017/12/08/positive-news-coverage-somewhat-unlikely-to-impact-pacific-biosciences-of-california-pacb-stock-price.html.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Insider Buying and Selling by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply